Other studies in B-ALL demonstrated Gal-9-dependent activation of tumoral AKT and ERK pathways, thus rationalizing Gal-9 inhibition as a promising therapeutic approach for patients with B-ALL and other hematologic malignancies [117]. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.